Style de citation APA (7e éd.)

M, T., G, O., G, T., C, W., MCT, F., A, R., . . . A, D. (2019). A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Dove Medical Press.

Style de citation Chicago (17e éd.)

M, Taylor, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, et Duggal A. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.

Style de citation MLA (8e éd.)

M, Taylor, et al. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.